TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00710749

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Disposable device
Description: Disposable urine flow meter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Disposable device
Description: Disposable urine flow meter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital device
Description: Digital urine flowmeter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital device
Description: Digital urine flowmeter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clinic flow measurement
Description: Clinic gold standard flow measurement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clinic flow measurement
Description: Clinic gold standard flow measurement
Study: NCT01934738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06273340
Description: Tablets, 100 mg TID, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets, TID, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06273340
Description: Tablets, to be decided dose, TID or titration, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets, TID or titration, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06273340
Description: Tablets, to be decided dose, TID or titration, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets, TID or titration, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06273340
Description: Tablets, to be decided dose, TID or titration, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets, TID or titration, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06273340
Description: Tablets, to be decided dose, TID or titration, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets, TID or titration, 14 days
Study: NCT00158574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPTi mefloquine
Description: IPTi doses 1 \& 2 at ages 2 \& 3 months, mefloquine 125mg IPTi dose 3 at 9 months, mefloquine 250mg
Study: NCT01934738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06273340
Description: Tablets, to be decided dose, TID or titration, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets, TID or titration, 14 days
Study: NCT05664282

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Damon self-ligating brackets
Study: NCT00158574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorproguanil dapsone
Description: IPTi doses 1 and 2 at ages 2 and 3 months, doses 15mg chlorproguanil and 18.75mg dapsone IPTi dose 3 at 9 months of age, doses 22.5mg chlorproguanil and 28.13mg dapsone
Study: NCT02144623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproate
Study: NCT05664282

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Victory self-ligating brackets
Study: NCT02632331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8825
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8825
Description: Oral
Study: NCT02040571

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed Loop
Description: A total of 24 participants with T1 Diabetes with sensor augmented insulin pump therapy (SAPT) experience will be recruited from four tertiary hospitals and will enter an un-masked randomised-control crossover trial, with a run-in period followed by two phases (in-hospital and at-home) in each of two stages (Closed Loop and Open Loop in random order). Closed Loop will be the intervention for this study, and its performance will be assessed compared to Open Loop (control treatment).
Study: NCT00912899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Noscapine HCl
Description: Escalating doses given twice per day
Study: NCT02896777

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transfer embryo from pH 7.20±0.02 on either Day 3 or day 5/6
Description: Post IVF/ICSI and according to the result of the randomization process, women will receive embryo from their oocytes that will be cultured in pH of 7.20±0.02.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transfer embryo from pH 7.3±0.02 either Day 3 or day 5/6
Description: Post IVF/ICSI and according to the result of the randomization process, women will receive embryo from their oocytes that will be cultured in pH of 7.3±0.02.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transfer embryo from pH of 7.4±0.02 on either Day 3 or day 5/6
Description: Post IVF/ICSI and according to the result of the randomization process, women will receive embryo from their oocytes that will be cultured in pH of 7.4±0.02 from day 0 to 5/6
Study: NCT03433365

Intervention type: OTHER
Intervention: MRD analysis
Description: To collect 2 samples for MRD analysis in patients treated with Lenalidomide
Study: NCT04625452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BBCC+5A's+GS
Description: It is a 5-steps intervention delivered in a motivational interviewing spirit. Clearly the five steps are asking about the behaviour risk factors, assessing the level of risk factors; providing information about the pros and cons of the behaviour in a neutral way; assessing the change by probing about the importance in and the confidence of changing the risk factor; assisting the patient to come-up with a road map about changing the risk factor, connecting the patient to support networks or drugs which can increase the likelihood to change; and arranging for the next visit.~All this given by asking opened question to participant, active listening, summarizing what he is saying, evoking change through concepts or statements, empathy and asking permission to provide further information.
Study: NCT00567736

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Disci/Rhus toxicodendron comp.®
Description: s.c. application 10 ml (1 ampul) in 5 to 10 parts on different back pain sites verum group 12 treatments: 8 in the first 4 weeks and 4 in the next 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo solution
Description: s.c. application 10 ml (1 ampul) in 5 to 10 parts on different back pain sites 12 treatments: 8 in the first 4 weeks and 4 in the next 4 weeks
Study: NCT00865098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Patients receive Cetuximab at an initial dose of 400 mg/m\^2 of Cetuximab to be infused 6 or 7 days before starting radiotherapy, followed by subsequent weekly infusions at a dose of 250 mg/m\^2 of Cetuximab and RT (72.0 Gy total in 42 fractions) for the next 6 weeks of the treatment course. Subjects will receive Cetuximab until radiographically documented progressive disease or unacceptable toxicity occurs or consent is withdrawn. If RT is delayed, administration of Cetuximab every 7 days is continued. If RT is discontinued for any reason, treatment with Cetuximab monotherapy every 7 days is continued.
Study: NCT03384706

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy (CPT)
Description: CPT looks at the impact the traumatic event has had on your life and helps you to examine and change unhelpful thoughts and feelings related to the event, yourself, others and the world.~CPT will be conducted in 5-15, 60 minute sessions held once or twice a week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accelerated Resolution Therapy (ART)
Description: ART, like CPT also involves processing thoughts and feelings related to the event, but does this in a different way relying more on visualization or imagination rather than talking.~ART will be conducted in 5-15, 60 minute sessions held once or twice a week.
Study: NCT00792727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoprofen Patch
Description: 2 topical patches applied once daily for 28 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: 2 topical placebo patches applied once daily for 28 days
Study: NCT00865631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 800 mg tablets, single dose (1 tablet)
Description: A: Experimental Subjects received Purepac formulated products under fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NEURONTIN® 400 mg capsules, single dose (2 capsules)
Description: B: Active comparator Subjects received Parke-Davis formulated products under non-fasting conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 800 mg tablets, single dose (1 tablet)
Description: A: Experimental Subjects received Purepac formulated products under non-fasting conditions
Study: NCT02040571

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Open Loop
Description: The performance of closed loop system will be compared to open loop system (Sensor Augmented Pump Therapy). Therefore, the Open Loop system will be the control treatment.~In stage 1 of study, participants are randomized to either closed loop (CL) or open loop (OL). In stage 2, all participants will be crossed to the opposite study arm.~Throughout the study, those who randomised to OL will receive exactly the same medical attention as the CL participants.
Study: NCT02760017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B. forficata

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04108013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: In the experimental group, 200mg SHR-1210 was given in the first day of each cycle, Carboplatin was given in the first day of each cycle, Paclitaxel-albumin was given in the first and eighth day of each cycle, with intravenous drip.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin and Paclitaxel-albumin
Description: In the control group, Carboplatin was given in the first day of each cycle, Paclitaxel-albumin was given in the first and eighth day of each cycle, with intravenous drip.
Study: NCT02568683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib
Description: ENTO spray dried dispersion tablets administered orally twice daily while in a fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: VCR administered intravenously
Study: NCT03875014

Intervention type: DEVICE
Intervention: surgery with implant for hip fracture
Description: hip replacement with bipolar hemiarthroplasty or total hip arthroplasty dual mobility done and patients was followed

Intervention type: DEVICE
Intervention: surgery with implant for hip fracture
Description: hip replacement with bipolar hemiarthroplasty or total hip arthroplasty dual mobility done and patients was followed
Study: NCT00971737

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: allogeneic GM-CSF-secreting breast cancer vaccine
Description: Given intradermally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic GM-CSF-secreting breast cancer vaccine
Description: Given intradermally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study: NCT02893527

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: personalized coaching
Description: personalized coaching coordinated by a coordinating nurse on a shutdown period of 8 months (consecutive stops).
Study: NCT00006604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV
Description: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV
Description: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV
Description: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV
Description: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV
Description: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Study: NCT03064308

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise Programme
Description: Participants will complete the High-Intensity Functional Exercise (HIFE) programme. The programme improves lower-limb strength, balance and mobility and all the exercises can be performed by the individual at home and with minimal equipment.
Study: NCT04442269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dupilumab
Description: Single-use prefilled glass syringe administered by subcutaneous (SC) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo
Study: NCT02848066

Intervention type: PROCEDURE
Intervention: Blood sample(10cc) collection
Description: In both groups, serum haptoglobins to be collected and analyzed

Intervention type: PROCEDURE
Intervention: Blood sample(10cc) collection
Description: In both groups, serum haptoglobins to be collected and analyzed
Study: NCT06440187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine+ nivolumab
Description: Gemcitabine+ nivolumab q 2wks
Study: NCT00411398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Namenda/Memantine
Description: 5mg tablets, 1-4 tabs by mouth per day
Study: NCT01546324

Intervention type: PROCEDURE
Intervention: Blood draw
Description: Maternal blood draw at approximately 8-17 weeks gestation.
Study: NCT01589614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: Tablet, 6mg, single

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804 + erythromycin
Description: PH-797804: tablet, 6mg, single erythromycin: tablet, 400 mg, multiple
Study: NCT00006604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV
Description: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV
Description: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV
Description: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Study: NCT00882089

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contura catheter
Description: Radiation therapy is delivered to a total dose of 34 Gy in 10 fractions bid over 5-7 days. Each day, the high dose rate iridium-192 brachytherapy treatments are separated by 6 hours. Each radiation treatment takes 15-30 minutes.
Study: NCT01627886

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibandronate sodium
Description: Ibandronate sodium Tablets 150 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate sodium
Description: Ibandronate sodium Tablets 150 mg
Study: NCT01233544

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SBRT or RFA
Description: Patients are allocated to one of the two arms in a 1:1 randomization

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SBRT or RFA
Description: Patients are allocated to one of the two arms in a 1:1 randomization
Study: NCT01623063

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hysteroscopy
Description: hysteroscopy with guided biopsies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Description: hysteroscopy with guided biopsies
Study: NCT02148848

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Description: Take risedronate 35 mg orally every week
Study: NCT01935453

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant hGM-CSF Herpes Simplex Virus Injection
Study: NCT03419182

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Reduction internal Fixation
Description: A surgeon uses hardware, such as plates and screws, to restore structural integrity and alignment of an acetabular fracture.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Reduction Internal Fixation with Total Hip Arthroscopy
Description: A surgeon uses hardware, such as plates and screws, to restore structural integrity and alignment of an acetabular fracture, and replaces the cartilage and bone of the greater trochanter with prosthetic components.
Study: NCT01673126

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anodal tDCS
Description: patients received anodal tDCS (on PFDL cortex) during 20 minutes preceded and followed by a behavioral assessment (Coma Recovery Scale Revised)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: Patient received a sham tDCS (5sec of stimulation). The device runs during 20minutes and the anode was placed over the DLPF cortex. A behavioral assessment preceded and followed the stimulation.
Study: NCT01329861

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Internet-based cognitive behavioural treatment
Description: Eight weeks internet-based cognitive behavioural treatment. Treatment consisted of education, cognitive skills acquisition, behavioural rehearsal, generalization and maintenance.
Study: NCT04445948

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40 milligrams Oral Tablet
Description: Proton Pump inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40 milligrams Oral Tablet
Description: Proton Pump inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40 milligrams Oral Tablet
Description: Proton Pump inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40 milligrams Oral Tablet
Description: Proton Pump inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin 1000 milligrams tablets
Description: Penicillin derivative antibiotic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin 1000 milligrams tablets
Description: Penicillin derivative antibiotic
Study: NCT02568683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: VCR administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: VCR administered intravenously
Study: NCT00891436

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone furoate nasal spray
Description: 2 sprays each nostril every morning for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: 2 sprays each nostril every morning for 2 weeks
Study: NCT02164214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept Treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etanercept Treatment
Study: NCT02624609

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control without pomegranate juice
Description: Control meal of 109 g white bread and 200 ml water (containing the same amount and type of sugars naturally present in pomegranate juice) to which the response of the test meal with pomegranate juice will be compared to.
Study: NCT04445948

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin 1000 milligrams tablets
Description: Penicillin derivative antibiotic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin 1000 milligrams tablets
Description: Penicillin derivative antibiotic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin 500 milligrams Tablets
Description: Macrolide antibiotic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin 500 milligrams Tablets
Description: Macrolide antibiotic
Study: NCT01284855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antivenom
Description: Polyvalent antivenom directed against Indian spectacled cobra (N. naja), common Indian krait (B. caeruleus), saw-scaled viper (Echis carinatus) and Russell's viper.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antivenom
Description: Polyvalent antivenom directed against Indian spectacled cobra (N. naja), common Indian krait (B. caeruleus), saw-scaled viper (Echis carinatus) and Russell's viper.
Study: NCT03919487

Intervention type: PROCEDURE
Intervention: Back to back colonoscopy
Description: After first colonoscopy performing with polypectomy, the 2nd colonoscopy will be performed right after the 1st colonoscopy, and if the missed lesion during the 1st colonoscopy will be found, it should be removed.
Study: NCT02182167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV N-acetylcysteine (NAC)
Study: NCT02624609

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test with pomegranate juice
Description: The test meal will contain 109 g white bread and 200 ml of pomegranate juice whose response will be compared to that of the control meal.
Study: NCT04445948

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin 500 milligrams Tablets
Description: Macrolide antibiotic
Study: NCT02182167

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Water
Study: NCT02202980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily
Study: NCT00474604

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diffusion-weighted magnetic resonance imaging
Description: A scan will be performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: diffusion-weighted magnetic resonance imaging
Description: A scan will be performed.
Study: NCT02202980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily